Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 1
1996 1
1998 2
1999 3
2000 2
2002 1
2003 1
2004 2
2006 2
2008 2
2014 1
2018 5
2019 1
2020 2
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

29 results
Results by year
Filters applied: . Clear all
Page 1
Coeliac disease and socio-economic status.
Stenhammar L, Högberg L, Ivarsson A, Laurin P, Myléus A, Fälth-Magnusson K. Stenhammar L, et al. Among authors: laurin p. Acta Paediatr. 2014 Aug;103(8):e328. doi: 10.1111/apa.12665. Epub 2014 May 16. Acta Paediatr. 2014. PMID: 24766430 No abstract available.
Fatty acid mimetic PBI-4547 restores metabolic homeostasis via GPR84 in mice with non-alcoholic fatty liver disease.
Simard JC, Thibodeau JF, Leduc M, Tremblay M, Laverdure A, Sarra-Bournet F, Gagnon W, Ouboudinar J, Gervais L, Felton A, Letourneau S, Geerts L, Cloutier MP, Hince K, Corpuz R, Blais A, Quintela VM, Duceppe JS, Abbott SD, Blais A, Zacharie B, Laurin P, Laplante SR, Kennedy CRJ, Hébert RL, Leblond FA, Grouix B, Gagnon L. Simard JC, et al. Among authors: laurin p. Sci Rep. 2020 Jul 29;10(1):12778. doi: 10.1038/s41598-020-69675-8. Sci Rep. 2020. PMID: 32728158 Free PMC article.
A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84.
Gagnon L, Leduc M, Thibodeau JF, Zhang MZ, Grouix B, Sarra-Bournet F, Gagnon W, Hince K, Tremblay M, Geerts L, Kennedy CRJ, Hébert RL, Gutsol A, Holterman CE, Kamto E, Gervais L, Ouboudinar J, Richard J, Felton A, Laverdure A, Simard JC, Létourneau S, Cloutier MP, Leblond FA, Abbott SD, Penney C, Duceppe JS, Zacharie B, Dupuis J, Calderone A, Nguyen QT, Harris RC, Laurin P. Gagnon L, et al. Among authors: laurin p. Am J Pathol. 2018 May;188(5):1132-1148. doi: 10.1016/j.ajpath.2018.01.009. Epub 2018 Feb 16. Am J Pathol. 2018. PMID: 29454750 Free article.
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis.
Khalil N, Manganas H, Ryerson CJ, Shapera S, Cantin AM, Hernandez P, Turcotte EE, Parker JM, Moran JE, Albert GR, Sawtell R, Hagerimana A, Laurin P, Gagnon L, Cesari F, Kolb M. Khalil N, et al. Among authors: laurin p. Eur Respir J. 2019 Mar 18;53(3):1800663. doi: 10.1183/13993003.00663-2018. Print 2019 Mar. Eur Respir J. 2019. PMID: 30578394 Free PMC article. Clinical Trial.
PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway.
Grouix B, Sarra-Bournet F, Leduc M, Simard JC, Hince K, Geerts L, Blais A, Gervais L, Laverdure A, Felton A, Richard J, Ouboudinar J, Gagnon W, Leblond FA, Laurin P, Gagnon L. Grouix B, et al. Among authors: laurin p. J Pharmacol Exp Ther. 2018 Oct;367(1):71-81. doi: 10.1124/jpet.118.250068. Epub 2018 Aug 9. J Pharmacol Exp Ther. 2018. PMID: 30093459
29 results